Aduro Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Personalized Immunotherapy pLADD Based … – GlobeNewswire (press release)
AppsforPCdaily |
Aduro Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Personalized Immunotherapy pLADD Based …
GlobeNewswire (press release) BERKELEY, Calif., Sept. 27, 2017 (GLOBE NEWSWIRE) — Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, announced today that the first patient has been dosed in the Phase 1 clinical trial … Reviewing Aduro Biotech (ADRO) and Catalyst Pharmaceuticals (CPRX) |
